China SXT Pharmaceuticals, Inc. Accumulated Other Comprehensive Income
China SXT Pharmaceuticals, Inc. (SXTC) had Accumulated Other Comprehensive Income of -$197.88 thousand as of 2026-03-31, per its 20-F filed 2026-07-01.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-07-01
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$197.88K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$766.99K.
- 2025-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$1.08M.
- 2024-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$568.85K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-03-31 | -$197.88K 20-F · filed 2026-07-01 |
| 2025-09-30 | -$766.99K 6-K · filed 2025-12-31 |
| 2025-03-31 | -$1.08M 20-F · filed 2026-07-01 |
| 2024-09-30 | -$568.85K 6-K · filed 2025-03-28 |
| 2024-03-31 | -$1.03M 20-F · filed 2025-07-31 |
| 2023-09-30 | -$1.02M 6-K · filed 2024-04-05 |
| 2023-03-31 | -$197.57K 20-F · filed 2024-08-13 |
| 2022-09-30 | -$779.39K 6-K · filed 2023-02-24 |
| 2022-03-31 | $956.14K 20-F · filed 2023-07-31 |
| 2021-09-30 | $758.82K 6-K · filed 2022-01-14 |
| 2021-03-31 | $527.79K 20-F/A · filed 2023-05-19 |
| 2020-09-30 | $48.12K 6-K · filed 2021-01-28 |
| 2020-03-31 | -$590.66K 20-F · filed 2021-08-13 |
| 2019-09-30 | -$756.92K 6-K/A · filed 2020-05-22 |
| 2019-03-31 | $50.40K 20-F · filed 2020-07-31 |
| 2018-03-31 | $257.37K 20-F · filed 2019-08-15 |